Saliva as a potential tool for diagnosis of dry mouth including Sjögren's syndrome

Ohyama, Keiko; Moriyama, Masafumi; Tanaka, Akihiko; Mitsui, Takashi; Ieda, Shinsuke; Furukawa, Soichi; Ohta, Miho; Imabayashi, Yumi; Nakamura, Seiji

doi:10.1111/odi.12252

Cited by 34 publications

(36 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Data from these reports congruently show significantly higher levels of Th1, Th2 and Th17 cytokines in saliva of pSS patients (28; 29; 30; 31) . However the lack of appropriate controls in the majority of these studies, in fact non-SS sicca patients, does not allow a definitive conclusion regarding the specificity of these salivary cytokines to discriminate pSS from non-SS sicca subjects.…”

Section: Saliva For Biomarker Discovery In Psssupporting

confidence: 54%

The Proteomics of Saliva in Sjögren's Syndrome

Katsiougiannis¹,

Wong²

2016

Rheumatic Disease Clinics of North America

View full text Add to dashboard Cite

Synopsis One of the main characteristics of primary Sjögren's syndrome (pSS) is chronic dysfunction and destruction of the salivary and lacrimal glands; hence, their secretory biofluids should reflect the glandular biological status. Saliva is a heterogeneous biofluid comprised of bio-molecules and omics constituents are altered in response to various diseases including pSS. In recent years, scientific effort has been undertaken for the purpose of evaluating saliva proteome to diagnose, monitor or prognosticate pSS. This review article overviews the recent advances in the field of salivary proteomics in the context of pSS, highlighting the most significant and promising findings. Determining saliva as a credible means of early disease detection could lead to translational advantages and significant clinical opportunities for pSS.

show abstract

Section: Saliva For Biomarker Discovery In Psssupporting

confidence: 54%

The Proteomics of Saliva in Sjögren's Syndrome

Katsiougiannis¹,

Wong²

2016

Rheumatic Disease Clinics of North America

View full text Add to dashboard Cite

show abstract

“…In addition, we record all reasons for study exclusion, disagreements between the 2 reviewers and third reviewer comments. Finally, 45 articles covering 65 studies are included in the meta‐analysis, with 31 articles including non‐sicca controls, 4 including non‐SS controls and 9 including both types of controls. The other included study compares IL‐17 expression between patients with pSS with weak or strong lymphocytic infiltration, although no control is involved.…”

Section: Resultsmentioning

confidence: 99%

Expression of interleukin‐17 in primary Sjögren's syndrome and the correlation with disease severity: A systematic review and meta‐analysis

et al. 2018

View full text Add to dashboard Cite

The aberrant expression of interleukin-17 (IL-17) has been reported in primary Sjögren's syndrome (pSS). Abnormalities in IL-17 can promote the production of pro-inflammatory cytokines and aggravate autoimmune disorders. The aim of this study was to investigate alterations of IL-17 in patients with pSS and explore the correlation between IL-17 and disease severity. Eight databases were searched for original studies reporting the expression of IL-17 in patients with pSS and controls. Eligible reports were included in the pooled analysis, and subgroup evaluations were performed according to different types of controls and IL-17 measurement methods. Newcastle-Ottawa Scale criteria were used to assess the risk of bias of the included studies. In total, 45 articles are included in the meta-analysis. The expression of IL-17 is significantly increased in patients with pSS compared to controls. Furthermore, patients with pSS without immunosuppressive treatment show markedly higher IL-17 levels. In addition, patients with pSS with positive rheumatoid factors tend to express a higher level of IL-17 than patients with negative rheumatoid factors. Negative correlations between IL-17 levels and ocular parameters are also found in patients with pSS. The results are similar after adjustment by "trim and fill" methods. In conclusion, the expression of IL-17 is obviously increased in patients with pSS, especially among those without immunosuppressive treatment. In addition, IL-17 level correlates with the disease severity of pSS. These findings demonstrate the significance of IL-17 overexpression in patients with pSS and may provide insights for the development of therapeutic interventions targeting IL-17 for pSS.

show abstract

“…Th17 cells secrete IL‐17, which constitutes a family of cytokines that includes six members, from A to F, with a wide range of biological activities . Recent studies have demonstrated the involvement of IL‐17 in autoimmune inflammation during the pathogenesis of pSS and have revealed elevated levels of IL‐17A in body fluids from patients with pSS, including tears, saliva and serum . An analysis of mouse models showed that IL‐17‐deficient mice were completely resistant to ESS induction, and adoptive transfer of Th17 cells drove the development of ESS in IL‐17 KO mice .…”

Section: Discussionmentioning

confidence: 99%

CP‐25 Alleviates Experimental Sjögren's Syndrome Features in NOD/Ltj Mice and Modulates T Lymphocyte Subsets

Zhang

et al. 2018

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Primary Sjögren's syndrome (pSS) is a chronic inflammatory autoimmune illness of the moisture-producing glands such as salivary glands that is characterized by various immune abnormalities. The aetiology of pSS remains unclear and there is no curative agent. In this study, we investigated the putative therapeutic effects on a NOD/Ltj mouse model of Sjögren's syndrome-like disorders of an ester derivative of paeoniflorin, paeoniflorin-6'O-benzene (termed CP-25). Our study showed that CP-25 alleviated effectively clinical manifestations in NOD/Ltj mice resulting, for example, in increased salivary flow and reduced histopathological scores. Furthermore, CP-25 decreased lymphocyte viability in NOD/Ltj mice and attenuated the infiltration of Th1 cells and Th2 cells into the salivary glands of NOD/Ltj mice. In the spleen on NOD/Ltj mice, CP-25 skewed the ratio of Th17 and regulatory T cells towards regulatory T cells. After treatment, concentrations of anti-La/SSB and IgG antibodies were reduced and the titre of the inflammatory cytokines IFN-γ, IL-4, IL-6 and IL-17A in the serum on NOD/Ltj mice was alleviated. Thus, we define CP-25 as a novel compound that is a potent therapeutic agent for pSS by modulating T lymphocyte subsets. Future studies will validate the use of CP-25 as a therapeutic strategy for the treatment of pSS.

show abstract

Saliva as a potential tool for diagnosis of dry mouth including Sjögren's syndrome

Abstract: The measurement of cytokines, CgA, and SIgA in saliva is suggested to be useful for the diagnosis of xerostomia and also to reveal disease status.

Cited by 34 publications

References 38 publications

The Proteomics of Saliva in Sjögren's Syndrome

The Proteomics of Saliva in Sjögren's Syndrome

Expression of interleukin‐17 in primary Sjögren's syndrome and the correlation with disease severity: A systematic review and meta‐analysis

CP‐25 Alleviates Experimental Sjögren's Syndrome Features in NOD/Ltj Mice and Modulates T Lymphocyte Subsets

Contact Info

Product

Resources

About